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Abstract
Introduction
Sex hormones have been implicated in the etiology of a number of diseases. To better
understand disease etiology and the mechanisms of disease-risk factor associations, this
analysis aimed to investigate the associations of anthropometric, sociodemographic and
behavioural factors with a range of circulating sex hormones and sex hormone-binding
globulin.
Methods
Statistical analyses of individual participant data from 12,330 male controls aged 25–85
years from 25 studies involved in the Endogenous Hormones Nutritional Biomarkers and
Prostate Cancer Collaborative Group. Analysis of variance was used to estimate geometric
means adjusted for study and relevant covariates.
Results
Older age was associated with higher concentrations of sex hormone-binding globulin and
dihydrotestosterone and lower concentrations of dehydroepiandrosterone sulfate, free tes-
tosterone, androstenedione, androstanediol glucuronide and free estradiol. Higher body
mass index was associated with higher concentrations of free estradiol, androstanediol glu-
curonide, estradiol and estrone and lower concentrations of dihydrotestosterone, testoster-
one, sex hormone-binding globulin, free testosterone, androstenedione and
dehydroepiandrosterone sulfate. Taller height was associated with lower concentrations of
androstenedione, testosterone, free testosterone and sex hormone-binding globulin and
higher concentrations of androstanediol glucuronide. Current smoking was associated with
higher concentrations of androstenedione, sex hormone-binding globulin and testosterone.
Alcohol consumption was associated with higher concentrations of dehydroepiandrosterone
sulfate, androstenedione and androstanediol glucuronide. East Asians had lower concentra-
tions of androstanediol glucuronide and African Americans had higher concentrations of
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estrogens. Education and marital status were modestly associated with a small number of
hormones.
Conclusion
Circulating sex hormones in men are strongly associated with age and body mass index,
and to a lesser extent with smoking status and alcohol consumption.
Introduction
Sex hormones in men are fundamental to many aspects of physiology. In the prostate,
androgens modulate cell proliferation, differentiation and apoptosis and have been theo-
rized to be involved in the etiology of prostate cancer. Although epidemiological studies
have found no consistent association between circulating sex hormone concentrations and
prostate cancer risk[1], nearly all metastatic prostate tumors overexpress deregulated
androgen receptors[2] and androgen deprivation therapy is a common treatment for meta-
static prostate cancer. Genome-wide association studies have also identified single nucleo-
tide polymorphisms associated with prostate cancer risk that interact with, or are localized
to, androgen receptors[3, 4]. In addition to their role in prostate cancer, sex hormones have
been implicated in the development of other common health outcomes, including hyperten-
sion, obesity, diabetes, cardiovascular and renal disease[5–7]. By understanding the deter-
minants of sex hormone concentrations, we may better comprehend disease etiology and
the mechanisms of disease-risk factor associations.
The Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative
Group (EHNBPCCG) was established to conduct collaborative pooled analyses of endogenous
hormones and nutritional biomarkers in relation to subsequent prostate cancer risk. This large
dataset also provides the opportunity to investigate the cross-sectional associations of anthro-
pometric, sociodemographic, behavioural and other factors with circulating sex hormone con-
centrations. Although many of these associations have been previously studied[8–12], this
collaborative dataset enables robust analyses to be performed for a range of hormones and par-
ticipant characteristics using unified methods. The large size of this dataset also provides
greater power to investigate the associations at extremes of the distribution for known relation-
ships, as well as the opportunity to examine novel associations.
Subjects and methods
Data collection
Principal investigators were invited to join the EHNBPCCG if they had published studies on
prostate cancer risk and circulating concentrations of sex hormones and/or nutritional bio-
markers from blood samples collected prior to the diagnosis of prostate cancer. These were
identified using literature search methods described previously[1]. Collaborators provided
data on circulating concentrations for up to seven different sex hormones and sex hormone-
binding globulin (SHBG) (Table 1) and a wide range of anthropometric, sociodemographic,
behavioural and medical factors.
All studies were either of a prospective cohort design[13–30] or were a prospective observa-
tional study within a randomized trial[31–36]. This analysis used secondary data, therefore
ethical approval for this analysis was not necessary. However, each study individually obtained
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ethical approval. Details of ethical approval, participant consent and study design can be found
in the original publications[13–36]. Participants were considered eligible for this analysis if
they had information on at least one of the circulating sex hormones or SHBG concentrations,
had not been diagnosed with prostate cancer by the time of censoring, were 25 years or over at
blood collection, had complete data on age at blood collection, height, and weight, and were
not known to be on androgen therapy at blood collection. Overall, these exclusion criteria
resulted in 12,330 participants (out of a total of 14,092; S1 Fig) from 25 studies being included
in these analyses (Table 2).
Free testosterone and free estradiol concentrations were calculated using the law of mass
action[37, 38] based on recorded SHBG, testosterone and estradiol values and assuming a con-
stant albumin concentration of 43 g/L.
Statistical analysis
Hormone and SHBG concentrations were logarithmically transformed to approximate normal
distributions. Categories investigated were selected a priori and cut-points chosen based on
sample size and the data distribution. The analyses examined associations of hormone concen-
trations with age (25–49 [mean age = 43.5], 50–54, 55–59, 60–64, 65–69, 70–74, 75+ years),
height (<160.0, 160.0–164.9, 165.0–169.9, 170.0–174.9, 175.0–179.9, 180.0–184.9, 185.0–189.9,
190.0+ cm), BMI (<20.0, 20.0–22.4, 22.5–24.9, 25.0–27.4, 27.5–29.9, 30.0–32.4, 32.5–34.9,
35.0–37.4, 37.5+ kg/m2), waist circumference (<90.0, 90.0–94.9, 95.0–99.9, 100.0–104.9, 105.0
+ cm) and waist-to-hip ratio (<0.900, 0.900–0.933, 0.934–0.966, 0.967–0.999, 1.000+). Health
behaviours investigated included smoking status (never, former, current:<15, 15–29, 30+ ciga-
rettes per day) and alcohol consumption (none, 1–9, 10–19, 20–29, 30–39, 40–49, 50–59, 60–
69, 70+ g alcohol per day). Ethnic/racial group was categorised as white, African American/
Caribbean, Hispanic/Latino, East Asian, and other ethnic/racial group. Other possible deter-
minants that were examined included: time of day of blood collection (before 09:00, 09:00–
11:59, 12:00–14:59, 15:00 onwards); educational status (no secondary/high school education,
secondary school, college and university); marital status (currently married/cohabiting, not
currently married/cohabiting) and family history of prostate cancer (no, yes: defined as a
father and/or brother diagnosed with prostate cancer).
Partial correlations between the sex hormones and SHBG were calculated using study-spe-
cific standardized values: (xjk-mj)/sj, where mj and sj denote the mean and standard deviation
of the log-transformed hormone concentrations in study j and xjk is an observation from that
study. These standardized values were adjusted for age at blood collection and BMI (included
as categorical variables, described above). Geometric mean concentrations of sex hormones
and SHBG were calculated using predicted values from analysis of variance models scaled to
the overall geometric mean concentration and adjusted for study, age at blood collection, and
BMI (with the exception of when we analysed the associations of age and BMI with hormone
concentrations, when these variables were not included as adjustment covariates). Analyses of
smoking and alcohol consumption were mutually adjusted for each other. To investigate the
relationship of hormone concentrations with ethnicity/race, studies were limited to the three
studies that had sufficient representation from men across multiple ethnic/racial groups
(Child Health and Development Studies, the Multi-Ethnic Cohort and the Prostate Cancer
Prevention Trial). Heterogeneity of means by category of each characteristic was tested using
the F test. Where appropriate, a test for trend was calculated using the analysis of variance test,
with the categorical variables entered as linear values scored consecutively as 1, 2, 3 etc. Owing
to the highly skewed distribution of alcohol consumption, the test for trend was calculated
based on median values within each category. To test for trend by smoking status, never and
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Table 2. Participant characteristics by study.
Study,
country
N (% of
total)
Mean
age,
years
(SD)
Age
range,
years
Year of
birth
Mean
height,
cm (SD)
Mean
BMI, kg/
m2 (SD)
% Current drinkers
(median daily
alcohol
consumption, g
alcohol)
% Current
smokers
(median
number of daily
cigarettes)
% White
ethnic
group
% Married/
cohabiting at
blood
collection
%
University
degree
% Family
history of
prostate
cancer
ATBC,
Finland
231
(1.9%)
60.5
(5.2)
50–69 1915–
1936
173.8
(6.8)
25.9
(3.7)
85.4 (8.5) 100 (20) - 82.3 5.6 2.5
BLSA, USA 112
(0.9%)
56.4
(12.8)
30–84 1895–
1948
176.8
(6.0)
25.7
(3.0)
- 21.4 95.5 91.8 57.1 -
CARET,
USA
300
(2.5%)
62.8
(6.0)
47–77 1913–
1945
174.9
(7.6)
27.7
(4.4)
68.2 (5) 50.0 (20) 93.7 85.9 24.2 3.3
CHDS, USA 396
(2.4%)
34.9
(3.2)
25–50 1912–
1941
178.7
(6.8)
24.7
(2.7)
77.5 (6) 50.6 (20) 63.1 99.7 34.5 -
EPIC,
Europe
638
(5.2%)
60.9
(6.2)
43–76 1918–
1952
172.6
(7.0)
27.0
(3.6)
87.1 (13) 27.8 (15) 100 89.1 22.9 -
EPIC
Norfolk,
Europe
707
(5.7%)
66.7
(6.5)
45–78 1918–
1950
172.9
(6.4)
26.6
(3.2)
73.8 (8) 9.3 99.9 88.3 12.5 1.7
FMC,
Finland
298
(2.4%)
57.9
(9.9)
33–80 1890–
1937
169.6
(6.8)
26.1
(3.5)
- 34.2 (15) 100 85.2 - -
HHS,
Finland
291
(2.4%)
51.0
(3.8)
40–56 1924–
1940
174.2
(6.2)
26.4
(3.1)
- - - - - -
HPFS, USA 682
(5.5%)
65.1
(7.4)
46–80 1913–
1946
178.1
(6.4)
26.0
(3.5)
73.5 (6) 3.9 (20) 99.4 93.0 100 10.3
JACC,
Japan
97
(0.8%)
67.8
(5.8)
58–83 1904–
1934
159.5
(7.1)
22.4
(2.7)
52.6 (2) 37.2 (20) 0 93.8 2.7 -
Janus,
Norway
1,153
(9.4%)
46.4
(4.2)
33–63 1910–
1947
176.2
(6.8)
25.1
(3.2)
- 62.5 (12) 100 - - -
JHCS 1988,
Japanese in
Hawaii
98
(0.8%)
63.4
(5.6)
52–74 1900–
1919
162.2
(5.4)
23.1
(2.8)
74.5 (5.5) 36.7 (20) 0 90.8 8.2 -
JHCS 1996,
Japanese in
Hawaii
139
(1.1%)
61.9
(5.7)
52–74 1900–
1919
162.8
(6.4)
23.2
(2.8)
78.4 (5) 28.1 (20) 0 94.2 10.1 -
JPHC,
Japan
399
(3.2%)
59.1
(6.6)
41–71 1923–
1949
162.0
(6.4)
23.3
(2.6)
71.2 (23) 40.6 (20) 0 91.0 - -
KPMCP,
USA
212
(1.7%)
71.8
(4.5)
60–85 1882–
1906
169.9
(6.7)
25.8
(3.1)
69.7 (10) 17.9 (30) 98.6 82.7 5.4 -
MCCS,
Australia
1,058
(8.6%)
58.3
(7.2)
40–72 1918–
1954
172.2
(7.3)
27.2
(3.7)
78.3 (13) 13.0 (20) 100 81.0 22.2 -
MEC, USA 922
(7.5%)
68.7
(7.2)
48–84 1918–
1948
174.2
(7.7)
27.1
(4.2)
90.9 (9) 12.6 (15) 13.2 78.1 32.2 9.0
MMAS,
USA
651
(5.3%)
57.6
(7.0)
41–70 1916–
1946
175.8
(7.2)
27.5
(4.5)
- 23.5 98.8 77.1 37.8 -
NSHDC E2,
Sweden
465
(3.8%)
57.6
(4.0)
40–61 1927–
1948
175.8
(5.9)
26.6
(3.5)
- 21.3 100 - - -
NSHDC
androg,
Sweden
382
(3.1%)
57.2
(4.5)
39–61 1927–
1958
175.8
(6.2)
26.5
(3.4)
100.0 (4) 17.4 100 85.6 12.4
PCPT, USA
and Canada
1,025
(8.3%)
63.3
(5.5)
55–83 1911–
1940
177.4
(7.0)
27.7
(4.0)
68.9 (3) 7.6 (20) 83.9 87.7 37.1 20.7
PHS, USA 376
(3.0%)
61.3
(7.5)
41–77 1905–
1941
177.9
(7.0)
24.6
(2.5)
84.4 (5) 8.5 (20) 96.5 - 100 -
PLCO, USA 858
(7.0%)
64.8
(4.8)
54–75 1919–
1944
177.9
(6.5)
27.4
(3.9)
70.0 (4) 9.1 (20) 100 86.9 42.2 6.1
ProtecT, UK 539
(4.4%)
61.5
(5.1)
50–70 1930–
1949
175.2
(6.5)
26.6
(3.5)
84.9 (18) 10.5 - - - 4.1
RBS, USA 301
(2.4%)
69.4
(9.0)
47–85 1898–
1938
174.4
(6.8)
26.0
(3.6)
68.8 (10) 7.3 (20) 100 90.4 22.6 -
Missing data
(%)
- - - - - - 31.1 12.2 9.0 26.3 27.3 55.5
(Continued)
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former smokers were combined and coded as 0; light, medium and heavy smokers were coded
as 1, 2 and 3, respectively.
Most variables had a small number of missing values (Table 2). Time of day at blood collec-
tion was missing for 44.8% of men and was therefore not included as a covariate in the analy-
ses. To enable adjustment for study, each study had to contain observations in a minimum of
two categories for each primary exposure to be included in the respective exposure analysis.
Assay methods for each hormone varied between studies (Table 1); some studies used “extrac-
tion” assays to measure circulating sex hormones (immunoassays preceded by extraction into
an organic solvent and celite column chromatography), which generally provide higher sensi-
tivity and specificity than non-extraction or “direct” assays. Heterogeneity between studies
and by assay method was tested using a study-by-factor and assay-by-factor interaction term
(fitted separately) in the analysis of variance, and assessed using the F test.
All statistical tests were two-sided and due to the multiple tests the statistical significance
threshold was p<0.01. Data analysis was carried out using Stata Statistical Software release
14.1 (Stata Corp., College Station, TX, USA).
Sensitivity analyses
To examine effect modification by these factors, separate analyses were performed strati-
fied by: age (<55, 55–69, 70+ years); BMI (<20.0, 20.0–29.9, 30.0+ kg/m2); and time of day
(morning and afternoon), in comparison to a restricted dataset. The analyses were also
repeated after restricting the dataset to: i) white men to examine whether ethnicity/race
was a confounder, ii) men with hormone concentrations that were within the range of
[lower quartile– 3interquartile range, upper quartile + 3interquartile range] of each
respective study to examine the effect of removing outliers (n = 63).
Results
25 studies contributed to the analysis, including 12,330 participants (Table 2). Participants
were born between 1882–1958 and age at blood collection ranged from 25–85 years
Table 2. (Continued)
Study,
country
N (% of
total)
Mean
age,
years
(SD)
Age
range,
years
Year of
birth
Mean
height,
cm (SD)
Mean
BMI, kg/
m2 (SD)
% Current drinkers
(median daily
alcohol
consumption, g
alcohol)
% Current
smokers
(median
number of daily
cigarettes)
% White
ethnic
group
% Married/
cohabiting at
blood
collection
%
University
degree
% Family
history of
prostate
cancer
Overall 12,330 59.9
(9.9)
25–85 1882–
1958
174.4
(7.8)
26.4
(3.8)
77.1 (8) 23.7 (20) 89.4 86.5 35.8 8.2
Abbreviations: ATBC = The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BLSA = The Baltimore Longitudinal Study of Aging; BMI = body
mass index; CARET = The Carotene and Retinol Efficacy Trial; CDHS = Child Health and Development Studies; EPIC = European Prospective
Investigation into Cancer and Nutrition; FMC = Finnish Mobile Clinic Health Examination Survey; HHS = Helsinki Heart Study; HPFS = Health Professionals
Follow-Up Study; JACC = Japan Collaborative Cohort Study; JPHC = Japan Public Health Center-based Prospective Study; JHCS = Japan-Hawaii Cancer
Study; KPMCP = Kaiser Permanente Medical Care Program; MCCS = Melbourne Collaborative Cohort Study; MEC = Multiethnic Cohort;
MMAS = Massachusetts Male Aging Study; NSHDC = Northern Sweden Health and Disease Cohort (androg = androgens; E2 = estradiol); PCPT = Prostate
Cancer Prevention Trial; PHS = Physicians’ Health Study; PLCO Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; ProtecT = Prostate
Testing for Cancer and Treatment; RBS = Ranch Bernardo Study; SD = standard deviation
https://doi.org/10.1371/journal.pone.0187741.t002
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(mean = 59.9 years; standard deviation = 9.9 years). The men were predominantly white
(89.4%).
Correlations between hormones
After taking into account age, BMI and study, most sex hormones were positively correlated
with each other (Table 3). Testosterone was most strongly correlated with free testosterone
(r = 0.77), DHT (r = 0.54) and SHBG (r = 0.52). DHEAS was correlated with androstenedione
(r = 0.40) and A-diol-G (r = 0.23). Estradiol was strongly correlated with free estradiol
(r = 0.88) and estrone (r = 0.54), and weakly correlated with SHBG (r = 0.10).
Age at blood collection
After adjusting for study and BMI, age was associated with concentrations of all hormones,
except testosterone and estradiol (Fig 1). Compared to men aged 50–54 years, those aged 75
+ years had circulating concentrations of DHEAS, free testosterone, androstenedione, A-diol-
G and free estradiol that were 50%, 27%, 26%, 17%, 16% lower, respectively. In contrast,
SHBG and DHT concentrations were 39% and 16% higher, respectively. There was significant
heterogeneity (P<0.01) between studies in the associations of free testosterone, DHT, estra-
diol, free estradiol, estrone and SHBG.
Although there was no evidence of a linear association between age and testosterone con-
centration, there was evidence of heterogeneity in the association of testosterone concentration
with age by time of day of blood collection (F = 3.00; P = 0.0005). For men whose blood was
collected in the morning, younger men (aged 50–54 years) had 10% higher circulating concen-
trations of total testosterone than those aged 75+ years, while age was not associated with total
testosterone concentration in men whose blood was collected in the afternoon (S2 Fig).
BMI
After adjusting for study and age, BMI was strongly associated with all sex hormones and
SHBG (Fig 2). Compared to men with a BMI 20.0–22.4 kg/m2, those with a BMI37.5 kg/m2
had concentrations of DHT, testosterone, SHBG, free testosterone, androstenedione and
Table 3. Partial correlation coefficients in control subjects between log-transformed concentrations of sex hormones and SHBG.
Androstenedione A-diol-G DHEAS Testosterone Free testosterone DHT Estradiol Free estradiol Estrone SHBG
Androstenedione 1
A-diol-G 0.23* 1
DHEAS 0.40* 0.21* 1
Testosterone 0.29* 0.25* 0.07* 1
Free testosterone 0.29* 0.28* 0.15* 0.77* 1
DHT 0.20* 0.22* 0.03 0.54* 0.34* 1
Estradiol 0.13* 0.14* 0.06* 0.33* 0.34* 0.19* 1
Free estradiol 0.09* 0.13* 0.11* 0.05* 0.37* -0.03 0.88* 1
Estrone 0.45* 0.18* 0.15 0.27* 0.26* 0.19* 0.54* 0.50* 1
SHBG 0.10* 0.04* -0.08* 0.52* -0.11* 0.36* 0.10* -0.36* 0.09* 1
Measurements are standardised by study and adjusted by age and BMI.
*P<0.01.
Abbreviations: A-diol-G = Androstanediol glucuronide; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-
binding globulin.
https://doi.org/10.1371/journal.pone.0187741.t003
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Fig 1. Relative geometric mean concentrations* of male sex hormones by age category. *relative to 50–54 years,
adjusted for study and BMI. #significant interaction with study P<0.01. Abbreviations: A-diol-G = Androstanediol
glucuronide; CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone;
SHBG = sex hormone-binding globulin.
https://doi.org/10.1371/journal.pone.0187741.g001
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Fig 2. Relative geometric mean concentrations* of male sex hormones by BMI category. *relative to BMI 20.0–22.4
kg/m2, adjusted for study and age. #significant interaction with study P<0.01. Abbreviations: A-diol-G = Androstanediol
glucuronide; CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone;
SHBG = sex hormone-binding globulin.
https://doi.org/10.1371/journal.pone.0187741.g002
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DHEAS that were 45%, 40%, 35%, 26%, 16% and 12% lower, respectively. In contrast, concen-
trations of free estradiol, A-diol-G, estradiol and estrone were 53%, 38%, 25% and 22% higher,
respectively. These associations remained broadly similar when using waist circumference or
WHR (S3 and S4 Figs), although when data were divided into fifths the magnitudes of the asso-
ciations were smaller with WHR than with BMI or waist circumference (data not shown). Dif-
ferences in geometric mean hormone concentrations by waist circumference and WHR were
attenuated following additional adjustment for BMI, although testosterone and SHBG
remained significantly associated with both waist circumference and WHR (S5 and S6 Figs).
Height
After adjusting for study, age and BMI, height was associated with concentrations of several
androgens and SHBG, but not estrogens (Fig 3). Compared to men with a height of 175–179
cm, those in the tallest category (190 cm) had concentrations of androstenedione, testoster-
one, free testosterone and SHBG that were 10%, 4%, 4%, and 2% lower, respectively, whilst A-
diol-G concentration was 4% higher.
Smoking
After adjusting for study, age, BMI and alcohol consumption, smoking status was positively
associated with concentrations of androgens and SHBG, but not estrogens (Fig 4). Compared
with never smokers, heavy smokers (30+ cigarettes/day) had concentrations of androstenedi-
one, SHBG and testosterone that were 24%, 11% and 6% higher, respectively.
Alcohol
After adjusting for study, age, BMI and smoking, alcohol consumption was associated with
higher concentrations of several androgens, but was not associated with estrogens (Fig 5). In
particular, compared with non-drinkers, those who drank70 g alcohol/day had a 28% higher
concentration of DHEAS. High alcohol consumption was also moderately associated with
higher concentrations of androstenedione and A-diol-G (11% and 6% higher, respectively).
Restricting the analysis to non-smokers (n = 6,953) did not materially alter these results.
Ethnic/racial group
After adjusting for study, age and BMI, most sex hormones did not differ by ethnic/racial
group, with the exception of A-diol-G and estrogens (Fig 6). Compared with white men, A-
diol-G concentration was 25% lower in East Asian men and 12% higher in Hispanic/Latino
men, while estrone, estradiol and free estradiol concentrations were 15%, 14% and 12% higher
in African American men than whites.
Time of blood collection
After adjusting for study, age and BMI, several sex hormones were associated with time of
blood collection (Fig 7). Compared with men whose blood was collected before 09:00, partici-
pants whose blood was collected at 15:00 or later had concentrations of androstenedione, tes-
tosterone, free testosterone and A-diol-G that were 19%, 16%, 15% and 8% lower, respectively.
Sociodemographic factors and health
After adjusting for study, age and BMI several sex hormones had small associations with socio-
demographic factors. In comparison to men with no secondary/high school qualifications,
men with a university education had concentrations of SHBG, androstenedione and
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Fig 3. Relative geometric mean concentrations* of male sex hormones by height categories. *relative to 175.0–
179.9 cm, adjusted for study, age and BMI. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence
interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
https://doi.org/10.1371/journal.pone.0187741.g003
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Fig 4. Relative geometric mean concentrations* of male sex hormones by smoking status. *relative to never smokers, adjusted for
study, age, BMI and alcohol consumption. #significant interaction with study P<0.01. Abbreviations: A-diol-G = Androstanediol glucuronide;
CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
https://doi.org/10.1371/journal.pone.0187741.g004
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testosterone and that were 7%, 6% and 5% lower, respectively (S7 Fig). In comparison to men
who were married/cohabiting, men who were not married/cohabiting had concentrations of
Fig 5. Relative geometric mean concentrations* of male sex hormones by alcohol consumption categories. *relative
to non-drinkers, adjusted for study, age, BMI and smoking status. Abbreviations: A-diol-G = Androstanediol glucuronide;
CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-
binding globulin.
https://doi.org/10.1371/journal.pone.0187741.g005
Fig 6. Relative geometric mean concentrations* of male sex hormones by ethnic/racial group. *relative to whites, adjusted for study,
age and BMI. #significant interaction with study P<0.01. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence interval;
DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
https://doi.org/10.1371/journal.pone.0187741.g006
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estrone, androstenedione, free estradiol and estradiol and that were 12%, 7%, 6% and 6%
higher, respectively (S8 Fig). Hormone concentrations were not associated with a family his-
tory of prostate cancer (S9 Fig).
Fig 7. Relative geometric mean concentrations* of male sex hormones by time of blood collection. *relative to before 09:00, adjusted
for study, age and BMI. #significant interaction with study P<0.01. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence
interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
https://doi.org/10.1371/journal.pone.0187741.g007
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Heterogeneity by study and assay
Some heterogeneity between studies in the associations of sex hormone concentrations with
anthropometric and sociodemographic factors was observed (see Figs 1–7). Much of the
observed heterogeneity was due to differences in the magnitude rather than the direction of
associations (data not shown). Some of the heterogeneity between studies may have been
caused by differences in assay type. There was heterogeneity by assay type in the associations
of DHT and estradiol concentrations with age. There was no increase in DHT with age in stud-
ies that used assays without an extraction step prior to assay, whilst age was associated with
higher DHT concentration in studies with an extraction step. For estradiol, the positive associ-
ation with age was stronger in studies that used an extraction step than in those that did not.
Sensitivity analyses
Stratification by age, BMI and time of day did not materially affect the results (data not
shown), with the exception of the association of total testosterone with age (see above). The
results also remained broadly unchanged after restricting the dataset to white men and exclud-
ing within study hormone outliers (data not shown).
Discussion
This international collaboration has brought together and analysed data from over 12,300 men
on the associations of various anthropometric, behavioural and sociodemographic factors with
circulating sex hormone and SHBG concentrations. Our findings suggest that age, body com-
position, and to a lesser extent smoking status and alcohol consumption, may be important
determinants of circulating sex hormone concentrations.
As expected, hormones were strongly correlated with other hormones close to them on the
sex steroid pathway (Fig 8). Testosterone is primarily secreted by the testes. The adrenal glands
are another source of androgens, including DHEAS and androstenedione, both of which can
ultimately be converted to testosterone and/or DHT in peripheral tissues. Androgens can also
be converted into estrogens, primarily in the testes and adipose tissue. <3% of circulating tes-
tosterone and estradiol is bioavailable to the tissues, or “free”, the remainder is primarily
bound to either SHBG or albumin[39].
Age was strongly associated with circulating SHBG and androgens, with the exception of
total testosterone concentration. Other studies have generally found that total testosterone
declines with age[12, 40–44], although more recent research suggests that the observed decline
may be partly due to confounding by obesity and comorbidities[45–49]. Our analyses found
no significant overall association of total testosterone with age. However, stratification by time
of day showed a significant linear decline with age only in men whose blood was collected in
the morning; circulating testosterone concentrations are highest in the morning and decline
throughout the day. However, this diurnal rhythm is blunted as men age[50, 51]. The marked
positive association of SHBG concentration with age may be related to a lower insulin-like
growth factor-1 concentration in older individuals[52]. Adrenal sensitivity to adrenocortico-
trophic hormone has also been shown to decline with age[53], which results in a substantially
reduced production of DHEAS and, to a lesser extent, androstenedione[54, 55]. Despite this
age-associated decline in androstenedione, DHT concentration was higher in older men,
which might be due to the reduced conversion of DHT to A-diol-G[56].
BMI was strongly associated with concentrations of all the sex hormones and SHBG. A
higher BMI was associated with markedly lower SHBG concentration, which may be due to
high insulin[57]. Some recent evidence indicates that this BMI-SHBG association may involve
low grade inflammation and/or increased liver fat[58, 59]. The reduction in SHBG may lead to
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a fall in testosterone production via a negative feedback loop. Increasing adipose tissue also
leads to higher aromatase activity[60], which converts androgens to estrogens, leading to
higher concentrations of circulating estrogens. This, together with the low concentrations of
SHBG, results in markedly higher concentrations of free estradiol in obese men. Our finding
of a strong linear association of A-diol-G concentration with BMI suggests an increase in
peripheral androgen metabolism with greater adiposity. Obesity leads to dysregulation of the
hypothalamic-pituitary-adrenal axis[57, 61] and may therefore result in lower DHEAS and
androstenedione production. After adjustment for BMI, waist circumference and WHR each
remained significantly associated with testosterone and SHBG concentrations. This suggests
that visceral fat, or other factors correlated with waist circumference and WHR, may be impor-
tant predictors of androgen and SHBG concentrations[62].
Testosterone, free testosterone and SHBG were weakly inversely associated with height,
and A-diol-G was positively associated with height. While estrogens are involved in the control
of growth in height[63] and affect growth hormone secretion[64], there is some evidence to
suggest that androgens may also be involved[65]. However, it is unclear to what extent circu-
lating sex hormone concentrations during childhood and adolescence correlate with concen-
trations later in life.
The mechanisms through which tobacco may affect hormone concentrations are complex
because cigarette smoke contains a wide range of endocrine disruptors, some of which exert
opposing physiological effects[66, 67]. Smoking was associated with higher concentrations of
testosterone and SHBG, which resulted in a relatively unchanged free testosterone concentra-
tion[68–70]. In our analysis smoking was also associated with elevated circulating androstene-
dione concentration.
Alcohol consumption was associated with moderately higher androgen concentrations, par-
ticularly for DHEAS, as observed previously[71–73], and to a lesser extent with androstenedione,
Fig 8. Simplified schematic of the biosynthesis pathway of sex hormones. Abbreviations: A-diol-
G = Androstanediol glucuronide; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone;
HSD = Hydroxysteroid dehydrogenase; HST = Hydroxysteroid sulfotransferase; UGT = Uridine 5’-diphospho-
glucuronosyltransferase.
https://doi.org/10.1371/journal.pone.0187741.g008
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possibly involving increased adrenal secretion and inhibition of hydroxysteroid dehydrogenase
[73]. The large association with DHEAS may be related to the long half-life of this metabolite.
Alcohol consumption was also moderately positively associated with A-diol-G, although findings
from other studies are inconsistent[74, 75]. While chronic excessive alcohol consumption is a
well-known cause of low testosterone in men[76], we did not find an inverse association of alco-
hol with testosterone concentration in the current analyses, perhaps because the levels of alcohol
intake were not sufficient to induce a detrimental biological effect.
Three studies provided data from men across several ethnic/racial groups and we found
that ethnic/racial group was significantly associated with circulating A-diol-G concentration,
which was lower in East Asian men compared to all other ethnic/racial groups, as observed
previously[77–79]. Estrone, estradiol and free estradiol concentration were also significantly
higher in African Americans, as reported elsewhere[80], although the mechanism for this
remains unclear. Further inference regarding the association between ethnicity/race and other
hormone concentrations was not possible due to the relatively low representation of non-
white men.
Heterogeneity between the included studies was present for several associations. Further
investigation showed that this was generally caused by differences in the magnitude of associa-
tion rather than the direction. Heterogeneity may have been caused by differences in sample
populations, study design, and for testosterone distribution of time of day of blood draw.
Additionally, some of the observed heterogeneity may have been attributable to differences in
assay type. In this analysis, no study used mass spectrometry, often considered the gold stan-
dard method of measurement for sex hormones[81]. Instead, the majority of sex hormones
were measured using extraction or non-extraction immunoassays. Non-extraction assays gen-
erally have a lower sensitivity and specificity for hormone concentrations than extraction
assays, and differences in assay performance may explain some of the differences observed in
hormone concentrations (Table 1).
The cross-sectional nature of this analysis means that it was not possible to determine
whether the associations found here are causal or due to reverse causation. Furthermore,
younger age groups are under-represented. Data regarding other potential confounders such
as physical activity and dietary factors were not collected in this centralized dataset, although
only weak associations with hormone concentrations have been reported[82, 83], therefore
any related confounding of the studied associations is likely to be small.
In summary, this analysis of individual participant data from 25 studies shows that circulat-
ing sex hormones in men are strongly associated with age and BMI, and to a lesser extent, with
smoking status and alcohol consumption. These associations may enable a greater understand-
ing of how risk factors are associated with the etiology of hormone-related diseases.
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